ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of "Buy" by Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $79.00.

ANIP has been the subject of a number of analyst reports. Guggenheim raised their price target on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 3rd. Leerink Partnrs upgraded ANI Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, December 11th. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 target price on the stock. Finally, StockNews.com cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, March 3rd.

ANI Pharmaceuticals Stock Up 4.4 %

NASDAQ ANIP opened at $61.40 on Wednesday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The company has a market capitalization of $1.29 billion, a P/E ratio of -111.64 and a beta of 0.63. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.81. The stock has a 50 day moving average price of $57.86 and a 200-day moving average price of $58.07.

Insider Activity

In related news, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the sale, the chief financial officer now directly owns 154,468 shares in the company, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,300 shares of company stock worth $584,869. 12.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after buying an additional 340,854 shares in the last quarter. Global Alpha Capital Management Ltd. boosted its holdings in ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock valued at $32,005,000 after purchasing an additional 9,500 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its holdings in ANI Pharmaceuticals by 17.6% during the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company's stock valued at $13,731,000 after purchasing an additional 34,416 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock valued at $777,000 after purchasing an additional 299 shares in the last quarter. Finally, Mizuho Markets Americas LLC acquired a new stake in ANI Pharmaceuticals during the third quarter valued at approximately $11,670,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads